These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11178122)

  • 1. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.
    Gravallese EM; Galson DL; Goldring SR; Auron PE
    Arthritis Res; 2001; 3(1):6-12. PubMed ID: 11178122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
    Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
    Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L; Schwarz EM; Boyce BF
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract]   [Full Text] [Related]  

  • 8. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
    Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
    J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S; Hata T
    Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Merger of bone biology and immunology].
    Suda T; Shima N; Higashio K
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract]   [Full Text] [Related]  

  • 14. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
    Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC
    Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
    [No Abstract]   [Full Text] [Related]  

  • 16. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.
    Frick KK; LaPlante K; Bushinsky DA
    Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1005-11. PubMed ID: 15972386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily.
    Galibert L; Tometsko ME; Anderson DM; Cosman D; Dougall WC
    J Biol Chem; 1998 Dec; 273(51):34120-7. PubMed ID: 9852070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.
    Tsukii K; Shima N; Mochizuki S; Yamaguchi K; Kinosaki M; Yano K; Shibata O; Udagawa N; Yasuda H; Suda T; Higashio K
    Biochem Biophys Res Commun; 1998 May; 246(2):337-41. PubMed ID: 9610359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.